amphotericin B

(redirected from Ambisome)
Also found in: Medical, Encyclopedia.

am·pho·ter·i·cin B

(ăm′fə-tĕr′ĭ-sĭn)
n.
An antibiotic, C47H73NO17, derived from strains of the actinomycete Streptomyces nodosus and used to treat systemic fungal infections.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Translations

amphotericin B

n anfotericina B
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Other product sales, which include products from chronic hepatitis B virus (HBV), cardiovascular, oncology and other categories inclusive of Vemlidy (tenofovir alafenamide 25 mg), Viread (tenofovir disoproxil fumarate 300 mg), Letairis (ambrisentan 5 mg and 10 mg), Ranexa(ranolazine 500 mg and 1000 mg), Zydelig (idelalisib 150 mg), AmBisome (amphotericin B liposome for injection 50 mg/vial) and Cayston (aztreonam for inhalation solution 75 mg/vial), were $604 million for the second quarter of 2019 compared to $807 million for the same period in 2018.
Other product sales, which include products from Gilead's chronic hepatitis B virus (HBV), cardiovascular, oncology and other categories inclusive of Vemlidy, Viread, Letairis, Ranexa, Zydelig and AmBisome, were $797 million in the quarter, down 10%.
Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Liposomal amphotericin B (Ambisome) in the treatment of complicated Kala-azar under the field conditions.
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
We treated the patient with liposomal amphotericin B (AmBisome [Gilead Sciences Ltd., London, UK) at a dose of 3 mg/kg given on days 1-5, and 7-day courses beginning on days 10 and 20.
Pappas et al., "Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study," Antimicrobial Agents and Chemotherapy, vol.
After assessing the clinical and laboratory findings of patients, 4 liposomal amphotericin-B (Ambisome; Gilead Turkey, Besiktas, Istanbul, Turkey) 3 mg/kg/day was started when no response was obtained to the empiric antibiotherapy for 7 days in the auto-HSCT group and for 5 days in the allo-HSCT group.
McEvoy et al., "Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients," Antimicrobial Agents and Chemotherapy, vol.
Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (ambisome) and DAMB.